Psychosis and schizophrenia<\/a> greatly impact the brain\u2019s normal processes, which interfere with the ability to think clearly. When symptoms of these disorders are uncontrolled, patients may struggle to function in daily life. However, patients often thrive when properly diagnosed and treated under the close supervision of a psychiatric mental health practitioner. For this Assignment, as you examine the patient case study in this week\u2019s Learning Resources, consider how you might assess and treat patients presenting with psychosis and schizophrenia.<\/p>\n Examine\u00a0Case Study: Pakistani Woman With Delusional Thought Processes.<\/em>\u00a0You will be asked to make three decisions concerning the medication to prescribe to this patient. Be sure to consider factors that might impact the patient\u2019s pharmacokinetic and pharmacodynamic processes<\/a>.<\/p>\n At each decision point, you should evaluate all options before selecting your decision and moving throughout the exercise. Before you make your decision, make sure that you have researched each option and that you evaluate the decision that you will select. Be sure to research each option using the primary literature.<\/p>\n Note:<\/em><\/strong>\u00a0Support your rationale with a minimum of five academic resources. While you may use the course text to support your rationale, it will not count toward the resource requirement. You should be utilizing the primary and secondary literature.<\/em><\/p>\n Reminder : The College of Nursing requires that all papers submitted include a title page, introduction, summary, and references. The Sample Paper provided at the Walden Writing Center provides an example of those required elements (available at https:\/\/academicguides.waldenu.edu\/writingcenter\/templates\/general#s-lg-box-20293632). All papers submitted must use this formatting.<\/a><\/strong><\/p>\n <\/p>\n Required Readings (click to expand\/reduce) <\/a><\/strong><\/p>\n <\/p>\n Freudenreich, O., Goff, D. C., & Henderson, D. C. (2016). Antipsychotic drugs. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), Massachusetts General Hospital psychopharmacology and neurotherapeutics<\/em>\u00a0(pp. 72\u201385). Elsevier.<\/p>\n American Psychiatric Association. (2019). Practice guideline for the treatment of patients with schizophrenia<\/em>. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Practice\/Clinical%20Practice%20Guidelines\/APA-Draft-Schizophrenia-Treatment-Guideline.pdf<\/a><\/p>\n Clozapine REMS. (2015). Clozapine REMS: The single shared system for clozapine<\/em>. https:\/\/www.clozapinerems.com\/CpmgClozapineUI\/rems\/pdf\/resources\/Clozapine_REMS_A_Guide_for_Healthcare_Providers.pdf<\/a><\/p>\n Funk, M. C., Beach, S. R., Bostwick, J. R., Celano, C. M., Hasnain, M., Pandurangi, A., Khandai, A., Taylor, A., Levenson, J. L., Riba, M., & Kovacs, R. J. (2018). Resource document on QTc prolongation and psychotropic medications<\/em>. American Psychiatric Association. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Directories\/Library-and-Archive\/resource_documents\/Resource-Document-2018-QTc-Prolongation-and-Psychotropic-Med.pdf<\/a><\/p>\n Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13<\/em>(2), 261\u2013276.\u00a0https:\/\/doi.org\/10.1093\/schbul\/13.2.261<\/a><\/p>\n Levenson, J. C., Kay, D. B., & Buysse, D. J. (2015). The pathophysiology of insomnia. Chest, 147<\/em>(4), 1179\u20131192. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4388122\/<\/a><\/p>\n McClellan, J. & Stock. S. (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 52<\/em>(9), 976\u2013990. https:\/\/www.jaacap.org\/article\/S0890-8567(09)62600-9\/pdf<\/a><\/p>\n Naber, D., & Lambert, M. (2009). The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians. CNS Drugs, 23<\/em>(8), 649\u2013659. https:\/\/doi.org\/10.2165\/00023210-200923080-00002<\/a><\/p>\n <\/p>\n Medication Resources (click to expand\/reduce) <\/a><\/strong><\/p>\n <\/p>\n U.S. Food & Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs<\/em>. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm<\/a><\/p>\n <\/p>\n Note:\u00a0<\/strong>To access the following medications, use the Drugs@FDA resource. Type the name of each medication in the keyword search bar. Select the hyperlink related to the medication name you searched. Review the supplements provided and select the package label resource file associated with the medication you searched. If a label is not available, you may need to conduct a general search outside of this resource provided. Be sure to review the label information for each medication as this information will be helpful for your review in preparation for your Assignments.<\/p>\nTo prepare for this Assignment:<\/strong><\/h2>\n
\n
The Assignment: 5 pages<\/strong><\/h2>\n
Introduction to the case (1 page)<\/strong><\/h2>\n
\n
![\"NURS](\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2021\/10\/NURS-6630-Assessing-and-Treating-Patients-With-Psychosis-and-Schizophrenia-300x132.png\")
Decision #1 (1 page)<\/strong><\/h2>\n
\n
Decision #2 (1 page)<\/strong><\/h2>\n
\n
Click here to ORDER an A++ paper from our MASTERS and DOCTORATE WRITERS: NURS 6630 Assessing and Treating Patients With Psychosis and Schizophrenia<\/strong><\/a><\/span><\/em><\/h3>\n<\/li>\n<\/ul>\n
<\/h3>\n
Decision #3 (1 page)<\/strong><\/h2>\n
\n
Conclusion (1 page)<\/strong><\/h2>\n
\n
Learning Resources<\/strong><\/h2>\n